Thomas W. Flaig, University of Colorado Cancer Center (IMAGE)

University of Colorado Anschutz

Thomas W. Flaig, University of Colorado Cancer Center

Caption

Thomas W. Flaig, MD, and colleagues show benefit of docetaxel after targeted anti-androgen therapy abiraterone.

Credit

University of Colorado Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.